Neurotec Pharma   Report issue

For profit Phase 2
Founded: Barcelona Spain (2006)
Status: Defunct (2014)

Organization Overview

First Clinical Trial
2011
NCT01428726
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2011

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 2 Trials (1)

nt-ko-003 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Multiple Sclerosis (Phase 2)

Multiple Sclerosis, Relapsing-Remitting (Phase 2)

Sclerosis (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 1